Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 6/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034019 | 0.93 | HSD17B10 (0.53) | CYP3A4CYP1A2HSD17B10NAMPTCYP2C19 | |
| SCHEMBL484820 | 0.89 | HSD17B10 (0.49) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 | |
| SCHEMBL27036544 | 0.89 | HSD17B10 (0.49) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 | |
| SCHEMBL3353242 | 0.89 | CYP3A4 (0.58) | CYP3A4CYP1A2HSD17B10NAMPTCYP2C19 | |
| SCHEMBL27227211 | 0.89 | HSD17B10 (0.49) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 | |
| SCHEMBL29172879 | 0.87 | CYP3A4 (0.42) | CYP3A4CYP1A2HSD17B10NAMPTCYP2C19 | |
| SCHEMBL1222909 | 0.86 | HSD17B10 (0.60) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 | |
| SCHEMBL13051068 | 0.85 | CYP3A4 (0.47) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 | |
| SCHEMBL18047936 | 0.84 | HSD17B10 (0.43) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 | |
| SCHEMBL16344528 | 0.83 | L3MBTL3 (0.43) | CYP3A4CYP1A2HSD17B10NAMPTL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023064370-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-2978425-A2 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014160592-A2 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2773351-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013066718-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007061978-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |